BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/480/0.1/20.12.24 | Delayed Deutsche Boerse AG 09:34:06 08/07/2024 BST | ||
| 2.96 EUR | +1.37% |
|
| Current month | -4.26% | ||
| 1 month | -7.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/07/24 | 2.96 | +1.37% |
| 05/07/24 | 2.92 | -7.89% |
| 04/07/24 | 3.17 | -2.16% |
| 03/07/24 | 3.24 | +5.88% |
| 02/07/24 | 3.06 | -5.56% |
Delayed Quote Deutsche Boerse AG
Last update July 08, 2024 at 09:34 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VD6YYV |
| ISIN | DE000VD6YYV2 |
| Date issued | 28/05/2024 |
| Strike | 480 $ |
| Maturity | 20/12/2024 (166 Days) |
| Parity | 10 : 1 |
| Emission price | 3.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.19 € |
|---|---|
| Lowest since issue | 2.92 € |
| Spread | 0.08 € |
| Spread % | 2.62% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
